BOT 1.43% 34.5¢ botanix pharmaceuticals ltd

It's synthetic, yes, but chemically identical so it's still a...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,381 Posts.
    lightbulb Created with Sketch. 429
    It's synthetic, yes, but chemically identical so it's still a cannabinoid.  As for it being "proprietary"... I don't think you can patent naturally occurring substances and furthermore they don't actually make the CBD themselves, it's manufactured by another company in the US.

    Botanix will benefit from first mover advantage getting CBD approved as a pharmaceutical for human use against acne and dermatitis, which blocks other companies from doing the same thing, hence they effectively gain a monopoly on CBD for those diseases.

    Permetrex is also another competitive advantage, ensuring more CBD enters the dermis than direct topical application alone.


    Last edited by refresher: 04/03/19
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.